WO2026064751 - TREATING PEDIATRIC CANCERS WITH HYDROXYUREAMETHYL ACYLFULVENE
National phase entry is expected:
Publication Number
WO/2026/064751
Publication Date
26.03.2026
International Application No.
PCT/US2025/047430
International Filing Date
22.09.2025
Title **
[English]
TREATING PEDIATRIC CANCERS WITH HYDROXYUREAMETHYL ACYLFULVENE
[French]
TRAITEMENT DE CANCERS PÉDIATRIQUES AU MOYEN D'HYDROXYURÉE-MÉTHYL-ACYLFULVÈNE
Applicants **
LANTERN PHARMA INC.
Inventors
BHATIA, Kishor
KULKARNI, Aditya
Priority Data
63/697,914
23.09.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2580 | |
| EPO | Filing, Examination, Granting | 19421 | |
| Japan | Filing, Examination, Granting | 2618 | |
| South Korea | Filing, Examination, Granting | 3134 | |
| USA | Filing, Examination, Granting | 12910 |
Total:
40,663
Contact Us
Abstract[English]
Disclosed are methods, compositions, and kits for treating pediatric cancers using hydroxyureamethyl acylfulvene (LP-184) or pharmaceutically acceptable salts/solvates thereof. The methods include monotherapy and combination regimens for pediatric sarcoma, medulloblastoma, glioma (including DIPG), hepatoblastoma, Wilms tumor, and related malignancies. Combination therapies include LP-184 with vincristine, topoisomerase I poisons (topotecan or irinotecan), PARP inhibitors (e.g., rucaparib), or spironolactone, yielding additive or greater-than-additive reductions in tumor growth or cell viability.[French]
L'invention concerne des procédés, des compositions et des kits pour traiter des cancers pédiatriques au moyen d'hydroxyurée-méthyl-acylfulvène (LP-184) ou de sels/solvates pharmaceutiquement acceptables de celui-ci. Les procédés comprennent une monothérapie et des régimes combinés pour un sarcome pédiatrique, un médulloblastome, un gliome (y compris DIPG), un hépatoblastome, une tumeur de Wilms et des malignités associées. Les polythérapies comprennent le LP-184 avec de la vincristine, des poisons de topoisomérase I (topotécan ou irinotécan), des inhibiteurs de PARP (p. ex. rucaparib), ou de la spironolactone, produisant des réductions d'additif ou supérieures à l'additif de la croissance tumorale ou de la viabilité cellulaire.